Comparing shorter versus longer steroids for giant cell arteritis
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial compares two different lengths of steroid treatment for giant cell arteritis, an inflammatory blood vessel disease. Participants receive the medication tocilizumab along with either 8 weeks or 26 weeks of prednisone, to see if a shorter course is just as safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of giant cell arteritis (GCA).
- You are starting tocilizumab as part of your normal treatment.
- You take at least 20 mg per day of prednisone (or an equivalent steroid) at the start.
- You agree to give your written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study tracks how quickly your C-reactive protein (CRP) level, a marker of inflammation, drops after you start taking steroids (glucocorticoids) for giant cell arteritis. The goal is to find better ways to monitor treatment response in this condition.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.